Hiperprolaktinemi ve erektil disfonksiyon
Yıl: 2018 Cilt: 20 Sayı: 3 Sayfa Aralığı: 90 - 94 Metin Dili: Türkçe DOI: 10.24898/tandro.2018.69672 İndeks Tarihi: 27-02-2019
Hiperprolaktinemi ve erektil disfonksiyon
Öz: Prolaktin ön hipofizden sentezlenerek dolaşıma katılan bir hormondur.Prolaktinin aşırı salınımı erkeklerde başta infertilite ve erektil disfonksiyon(ED) olmak üzere birtakım bulgular ile karşımıza çıkabilmektedir.Hiperprolaktinemi nadir görülen bir durum olmasına karşın erkek cinselfonksiyon bozukluğunun düzeltilebilir bir nedenidir. Hiperprolaktinemisaptanan hastalarda dopamin agonistleri ile yaklaşık %90 oranlarındatedavi mümkündür. Bu nedenle, özellikle testosteron düşüklüğü olanerektil disfonksiyonlu hastalarda serum prolaktin düzeyi ölçümü akıldatutulması gereken, önemli bir testtir.Sağlık Bilimleri Üniversitesi, Ankara Numune Eğitim ve Araştırma Hastanesi, Üroloji A Kliniği, Ankara, Türkiye
Anahtar Kelime: Konular:
Hyperprolactinemia and erectile dysfunction
Öz: Prolactin is a hormone that is synthesized and released in systemic circulation from the anterior pituitary gland. Excessive prolactin release can be associated with some findings, especially loss of libido, infertility, and erectile dysfunction (ED) in men. Although hyperprolactinemia is a rare condition, it is a correctable cause of male sexual dysfunction. In patients with hyperprolactinemia, treatment is possible with dopamine agonists about 90% of the patients. Therefore, measurement of serum prolactin levels in patients with erectile dysfunction, especially those with low testosterone, is an important test that must be kept in mind.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Becker KL, Kahn CR, Rebar RW. Prolactin and its disorders. Chapter 13. Principles and Practice of Endocrinology and Metabolism, 3rd ed. Philadelphia PA: Lippincott Williams & Wilkins; 2002. p.37.
- Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365–74. [CrossRef]
- Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol 2011;7:267–78. [CrossRef]
- Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003;2:23–32. [CrossRef]
- Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37:67– 99. [CrossRef]
- Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999;44(Suppl 12):1085–90.
- Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Arch Neurol 2006;63:729. [CrossRef]
- Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–9. [CrossRef] https:// doi.org/10.1002/cncr.20412
- Buvat J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 2003;15:373–7. [CrossRef]
- Studer LH, Aylwin AS. Elevated prolactin levels among adult male sex offenders. Psychol Rep 2006;98:841–8. [CrossRef]
- Bolyakov A, Paduch DA. Prolactin in men’s health and disease. Curr Opin Urol 2011;21:527–34. [CrossRef]
- Zolbanin NM, Zolali E, Nayebi AM. Testosterone replacement attenuates haloperidol-induced catalepsy in male rats. Adv Pharm Bull 2014;4:237–41. [CrossRef]
- Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, et al. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 2007;4:1485–93. [CrossRef]
- Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med 2013;10:661–77. [CrossRef]
- Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction. Rev Urol 2000;2:39–42.
- Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014;28:421–53. [CrossRef]
- Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamicpituitary-gonadal axis. J Clin Psychopharmacol 2002;22:109–14. [CrossRef]
- Berek JS. Prolaktin anomallikleri. Bölüm 5. Berek & Novak Jinekoloji, 13. Baskı. Adana: Nobel Kitabevi; 2004. p.896.
- Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis 2004;11:337–41. [CrossRef]
- Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44(Suppl 12):1075–84.
- Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005;42:175–92. [CrossRef]
- Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008;11:141– 6. [CrossRef]
- Hattori N, Aisaka K, Shimatsu A. A possible cause of the variable detectability of macroprolactin by different immunoassay systems. Clin Chem Lab Med 2016;54. [CrossRef]
- Green AI, Sherlock M, Stewart PM, Gittoes NJ, Toogood AA. Extensive experience in the management of macroprolactinomas. Clin Endocrinol (Oxf) 2014;81:85–92. [CrossRef]
- Sadideen H, Swaminathan R. Macroprolactin: what is it and what is its importance? Int J Clin Pract 2006;60:457–61. [CrossRef]
- Whyte MB, Pramodh S, Srikugan L, Gilbert JA, Miell JP, Sherwood RA, et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 2015;18:319–25. [CrossRef]
- Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Longterm follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996;45:299–303. [CrossRef]
- Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999;44:254–61. [CrossRef]
- Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 2003;169:575–81.
- Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM 2013;106:495–504. [CrossRef]
- Harisaran V, Cone E, Hwang K. Specific Endocrinopathies and Male Infertility. In: Kavoussi PK, et al., editors. Clinical Urologic Endocrinology. London: Springer-Verlag; 2013. p.123–37.
- Van’t Verlaat JW, Croughs RJM. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf)1991;34:175–8. [CrossRef]
- Webster J. Clinical management of prolactinomas. Best Pract Res Clin Endocrinol Metab 1999;13:395–408. [CrossRef]
- Xue XC, Jiang S, Yin SL, Zhong CH, Zhou PZ, Cheng SW. Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function. Sichuan Da Xue Xue Bao Yi Xue Ban 2013;44:452–7
- Colao A, Lombardi G, Annunziato L. Cabergoline. Exp Opin Pharmacother 2000;1:555–74. [CrossRef]
- Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hiperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–22. [CrossRef]
- Nickel M, Moleda D, Loew T, Rother W, Pedrosa Gil F. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res 2007;19:104–7. [CrossRef]
- Arduc A, Gokay F, Isik S, Ozuguz U, Akbaba G, Tutuncu Y, et al. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. J Endocrinol Invest 2015;38:447–53. [CrossRef]
- Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000;53:53–60. [CrossRef]
- Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O, et al. Long-term treatment of macroprolactinomas with CV 205– 502. Eur J Endocrinol 1993;128:301–7. [CrossRef]
- Glezer A, Bronstein MD. Prolactinomas. Endocrinol Metab Clin North Am 2015;44:71–8. [CrossRef]
- Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 2015;22:1785–91. [CrossRef]
- Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir (Wien) 2003;145:935–40; discussion 940–1. [CrossRef]
- Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002;87:3578–82. [CrossRef]
| APA | güzel ö, Atan A, ASLAN Y (2018). Hiperprolaktinemi ve erektil disfonksiyon. , 90 - 94. 10.24898/tandro.2018.69672 |
| Chicago | güzel özer,Atan Ali,ASLAN YILMAZ Hiperprolaktinemi ve erektil disfonksiyon. (2018): 90 - 94. 10.24898/tandro.2018.69672 |
| MLA | güzel özer,Atan Ali,ASLAN YILMAZ Hiperprolaktinemi ve erektil disfonksiyon. , 2018, ss.90 - 94. 10.24898/tandro.2018.69672 |
| AMA | güzel ö,Atan A,ASLAN Y Hiperprolaktinemi ve erektil disfonksiyon. . 2018; 90 - 94. 10.24898/tandro.2018.69672 |
| Vancouver | güzel ö,Atan A,ASLAN Y Hiperprolaktinemi ve erektil disfonksiyon. . 2018; 90 - 94. 10.24898/tandro.2018.69672 |
| IEEE | güzel ö,Atan A,ASLAN Y "Hiperprolaktinemi ve erektil disfonksiyon." , ss.90 - 94, 2018. 10.24898/tandro.2018.69672 |
| ISNAD | güzel, özer vd. "Hiperprolaktinemi ve erektil disfonksiyon". (2018), 90-94. https://doi.org/10.24898/tandro.2018.69672 |
| APA | güzel ö, Atan A, ASLAN Y (2018). Hiperprolaktinemi ve erektil disfonksiyon. Androloji Bülteni, 20(3), 90 - 94. 10.24898/tandro.2018.69672 |
| Chicago | güzel özer,Atan Ali,ASLAN YILMAZ Hiperprolaktinemi ve erektil disfonksiyon. Androloji Bülteni 20, no.3 (2018): 90 - 94. 10.24898/tandro.2018.69672 |
| MLA | güzel özer,Atan Ali,ASLAN YILMAZ Hiperprolaktinemi ve erektil disfonksiyon. Androloji Bülteni, vol.20, no.3, 2018, ss.90 - 94. 10.24898/tandro.2018.69672 |
| AMA | güzel ö,Atan A,ASLAN Y Hiperprolaktinemi ve erektil disfonksiyon. Androloji Bülteni. 2018; 20(3): 90 - 94. 10.24898/tandro.2018.69672 |
| Vancouver | güzel ö,Atan A,ASLAN Y Hiperprolaktinemi ve erektil disfonksiyon. Androloji Bülteni. 2018; 20(3): 90 - 94. 10.24898/tandro.2018.69672 |
| IEEE | güzel ö,Atan A,ASLAN Y "Hiperprolaktinemi ve erektil disfonksiyon." Androloji Bülteni, 20, ss.90 - 94, 2018. 10.24898/tandro.2018.69672 |
| ISNAD | güzel, özer vd. "Hiperprolaktinemi ve erektil disfonksiyon". Androloji Bülteni 20/3 (2018), 90-94. https://doi.org/10.24898/tandro.2018.69672 |
